ID   MDA-PCa-2b
AC   CVCL_4748
SY   MDA PCa 2b; MDAPCa-2b; MDAPCa2b; MDAPCA2B; MDAPC2B; MDA2B; M.D. Anderson-Prostate Cancer-2b
DR   BTO; BTO:0005050
DR   CLO; CLO_0007629
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-2422
DR   BioSample; SAMN03471841
DR   BioSample; SAMN10988222
DR   CCLE; MDAPCA2B_PROSTATE
DR   Cosmic; 1689712
DR   Cosmic; 2651771
DR   Cosmic; 2669171
DR   DepMap; ACH-000952
DR   GEO; GSM91928
DR   GEO; GSM648821
DR   GEO; GSM887302
DR   GEO; GSM888377
DR   LiGeA; CCLE_281
DR   PharmacoDB; MDAPCa2b_896_2019
DR   Progenetix; CVCL_4748
DR   Wikidata; Q54904655
RX   PubMed=9815652;
RX   PubMed=12725112;
RX   PubMed=14518029;
RX   PubMed=15486987;
RX   PubMed=22460905;
RX   PubMed=23671654;
RX   PubMed=30787054;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: African American.
CC   Doubling time: 42-53 hours (in BRFF-HPC1 + 20% FBS), 61-73 hours (in F12K(+) + 20% FBS) (PubMed=9815652); 89.15 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   Microsatellite instability: Instable (MSI) (PubMed=23671654; PubMed=31068700;).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=90.02%; Native American=0%; East Asian, North=2.64%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=7.34% (PubMed=30894373).
CC   Derived from metastatic site: Bone.
ST   Source(s): ATCC; PubMed=14518029
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 10,11
ST   D18S51: 16,17
ST   D21S11: 33.2
ST   D3S1358: 14,17
ST   D5S818: 12,13
ST   D7S820: 8,10
ST   D8S1179: 14,15
ST   FGA: 20,22
ST   TH01: 8,9
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_4747 ! MDA-PCa-2a
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-01-21; Version: 25
//
RX   PubMed=9815652;
RA   Navone N.M., Olive M., Ozen M., Davis R., Troncoso P., Tu S.-M.,
RA   Johnston D., Pollack A., Pathak S., von Eschenbach A.C.,
RA   Logothetis C.J.;
RT   "Establishment of two human prostate cancer cell lines derived from a
RT   single bone metastasis.";
RL   Clin. Cancer Res. 3:2493-2500(1997).
//
RX   PubMed=12725112; DOI=10.1385/1-59259-372-0:21;
RA   Russell P.J., Kingsley E.A.;
RT   "Human prostate cancer cell lines.";
RL   Methods Mol. Med. 81:21-39(2003).
//
RX   PubMed=14518029; DOI=10.1002/pros.10290;
RA   van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U.,
RA   Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.;
RT   "Molecular characterization of human prostate carcinoma cell lines.";
RL   Prostate 57:205-225(2003).
//
RX   PubMed=15486987; DOI=10.1002/pros.20158;
RA   Zhao H., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R.,
RA   Brooks J.D.;
RT   "Genome-wide characterization of gene expression variations and DNA
RT   copy number changes in prostate cancer cell lines.";
RL   Prostate 63:187-197(2005).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;
RA   Lu Y., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
//
RX   PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132;
RA   Hooker S.E., Woods-Burnham L., Bathina M., Lloyd S.M., Gorjala P.,
RA   Mitra R., Nonn L., Kimbro K.S., Kittles R.;
RT   "Genetic ancestry analysis reveals misclassification of commonly used
RT   cancer cell lines.";
RL   Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574-3574(2019).
//